Why have so many R&D consortia been created over the last several years in the pharmaceutical industry? How many are there? As new ones emerge, is there overlap with the goals of existing consortia? What are some of the best practices in managing these collaborations?
ELIXIR and the Pistoia Alliance will be collaborating as part of the Map of Alliances project, an industry initiative to better understand the landscape of the pre-competitive environment in life sciences.
At a very productive meeting last week at the ELIXIR Hub in Hinxton, near Cambridge, John Wise and Richard Holland of the Pistoia Alliance worked with Andrew Smith, Premysl Velek and Rafael Jimenez of ELIXIR to understand the intentions and requirements of both parties, and established that much of what we were doing was very similar, if not identical.
The Map of Alliances project will catalogue the various life sciences consortia, partnerships, foundations and alliances in the life sciences sector and investigate how these collaborative efforts form an interconnected web of partnerships.
The landscape of alliances, foundations, partnerships and consortia in the life sciences world is complex, with many organisations existing that may overlap in their aims or share a significant proportion of their membership. Understanding our place in this complex web of connections is essential for cost-effective and productive life science research.